Drugmaker GSK posts slumping Q1 profits

British drugs firm GlaxoSmithKline on Wednesday said its first-quarter net profit tumbled by almost a third, with the group hit by falling sales and a poor economic climate.

, which also has a large consumer healthcare division, confirmed that it planned to sell drinks brands Lucozade and Ribena as part of its European restructuring plans.

Profit after tax dived to £961 million ($1.47 billion, 1.12 billion euros) in the first quarter from £1.3 billion in the same part of 2012, the pharmaceuticals firm said in a results statement.

Pre-tax profit slid to £1.41 billion from £1.86 billion last time around.

Sales dropped three percent to £6.47 billion compared with the same period of last year, dented partly by the sale of GSK's non-core over-the-counter brands in 2012.

"The commercial environment in Europe remains challenging and unpredictable, and we continue to be cautious about the outlook here," chief executive Andrew Witty said in the statement.

He added that GSK had completed its strategic review into fruit-flavoured soft drink Ribena and energy drink Lucozade, which are both primarily established in Western markets.

"We... concluded that the tremendous growth potential of these iconic brands, particularly outside the core Western markets, could be better leveraged by companies with existing category presence and infrastructure in these regions," he said.

"As a result, we have decided to pursue the divestment of these brands, subject to the realisation of appropriate value for GSK shareholders."

Witty added that GSK was "on track" to deliver total annual savings of at least £1.0 billion by 2016, under a restructuring programme that was launched earlier this year.

GSK also ramped up its shareholder dividend by six percent to 18 pence per share.

However, 's share price fell 0.42 percent to 1,671.5 pence in late afternoon deals on London's FTSE 100 index of leading companies, which was 0.48 percent higher at 6,436.98 points.

Wednesday's result were published almost one week after GSK revealed that it had received a US recommendation for approval of its Breo Ellipta inhaler treatment for chronic obstructive pulmonary disease (COPD).

add to favorites email to friend print save as pdf

Related Stories

Drugmaker GSK reveals lower profits, restructuring

Feb 06, 2013

British drugs firm GlaxoSmithKline on Wednesday unveiled a 13-percent drop in annual net profits and outlined a plan for more restructuring in Europe to deliver greater savings and offset weaker sales across the region.

GlaxoSmithKline says net profits drop 13% in Q1

Apr 25, 2012

British drugsmaker GlaxoSmithKline said Wednesday that its net profits dropped 13 percent to £1.325 billion (1.616 billion euros, $2.134 billion) in the first quarter from a year earlier.

GlaxoSmithKline posts rising Q3 profits

Oct 26, 2011

British drugmaker GlaxoSmithKline said Wednesday that third-quarter net profit rose seven percent, boosted by growth across its main pharmaceuticals, vaccines and consumer healthcare divisions.

GlaxoSmithKline profits up on lower tax

Jul 25, 2012

British drugmaker GlaxoSmithKline on Wednesday said its second quarter net profit rose 13.3 percent from a year earlier to £1.25 billion ($1.94 billion, 1.59 billion euros).

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

11 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments